Trials / Conditions / Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

9 registered clinical trials studyying Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refracto NCT06649812	National Cancer Institute (NCI)	Phase 2
Recruiting	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049	Yazeed Sawalha	Phase 1 / Phase 2
Recruiting	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patien NCT05821088	David Bond, MD	Phase 2
Active Not Recruiting	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lym NCT05507541	Mayo Clinic	Phase 2
Recruiting	Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma NCT05755087	Lapo Alinari	Phase 1
Active Not Recruiting	Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin NCT05202782	Northwestern University	Phase 2
Active Not Recruiting	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lympho NCT03038672	National Cancer Institute (NCI)	Phase 2
Terminated	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Ac NCT03103971	Fred Hutchinson Cancer Center	Phase 1
Terminated	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT02706405	Fred Hutchinson Cancer Center	Phase 1